Oncological applications of positron emission tomography with fluorine-18 fluorodeoxyglucose

Kang

et al. 2011

Cancer

BACKGROUND: Metabolic activity assessed by 18 F-fluorodeoxyglocuse-positron emission tomography ( 18 F-FDG-PET) reflects biological aggressiveness and prognoses in various tumors. The authors present a correlation between tumor metabolic activity and clinical outcomes in patients with hepatocellular carcinoma (HCC). METHODS: Over a 3-year period (2005)(2006)(2007)(2008), 135 locally advanced HCC patients were treated with localized concurrent chemoradiotherapy (CCRT; external beam radiotherapy at 45 grays for 5 weeks plus concurrent hepatic arterial infusion of 5-fluorouracil during the first and fifth week) followed by repetitive hepatic arterial infusional chemotherapy with 5-fluorouracil and cisplatin. Among them, the authors studied 107 who received 18 F-FDG-PET before CCRT. Maximal standardized uptake values (SUVs) of tumors were calculated. RESULTS: The median maximal tumor SUV was 6.1 (range, 2.4-$19.2). Patients with low maximal tumor SUVs (<6.1) had a higher disease control rate than those with high maximal tumor SUVs (!6.1) (86.8% vs 68.5%, respectively, P ¼ .023). Both median progression-free survival (PFS; 8.4 vs 5.2 months; P ¼ .003) and overall survival (OS; 17.9 vs 11.3 months; P ¼ .013) were significantly longer in the low maximal tumor SUV group than in the high maximal tumor SUV group, respectively. In multivariate analysis, low maximal tumor SUV and objective responses to CCRT remained significant for PFS and OS. The high maximal tumor SUV group was more likely to have extrahepatic metastasis within 6 months than the low maximal tumor SUV group (58.1% vs 26.8%, respectively; P < .001). Similar results were obtained for the maximal tumor SUV/normal liver maximal SUV ratio (<2 vs !2) concerning progression, death, and extrahepatic metastasis. CONCLUSIONS: Metabolic activity may be useful not only in predicting prognosis and treatment responses, but also in establishing optimal treatment plans in locally advanced HCC. Cancer 2011;117:4779-

mentioning

confidence: 99%

¹⁸F‐fluorodeoxyglucose uptake on positron emission tomography as a prognostic predictor in locally advanced hepatocellular carcinoma

Kang

et al. 2011

Cancer

La Revue de Médecine Interne

“…Du fait de l'hypermétabolisme glucidique des cellules néoplasiques, la TEP au 18 FDG est aujourd'hui principalement pratiquée pour des indications oncologiques qui sont le diagnostic positif et le bilan d'extension des tumeurs primitives, la suspicion de récidive tumorale ou le suivi post-thérapeutique [13,14]. Certaines pathologies inflammatoires et infectieuses peuvent aussi fixer le 18 FDG de façon avide [15,16].…”

Section: Discussionunclassified

Maladie de Horton et atteintes artérielles extratemporales : utilité de la tomographie par émission de positons au 18FDG. À propos de trois observations et d'une revue de la littérature

Belhocine

Kaye

Delanaye

et al. 2002

RésuméPropos. -Chez trois patients atteints de maladie de Horton (MH), la tomographie par émission de positons (TEP) au 18 F-fluoro-2-déoxy-D-glucose ( 18 FDG) a montré un hypermétabolisme artériel au niveau de localisations extratemporales asymptomatiques. Méthodes. -Une TEP au 18 FDG a été réalisée chez 3 patients présentant un syndrome inflammatoire inexpliqué. L'examen a été pratiqué chez des sujets à jeun, 60 min après injection intraveineuse de 222 MBq de 18 FDG en moyenne. Résultats. -Dans les 3 observations, la TEP a objectivé un hypermétabolisme polyartériel asymptomatique, entreprenant les vaisseaux cervicothoraciques et abdominaux. Chez 2 patients, une artérite gigantocellulaire (AGC) est histologiquement confirmée. Dans le troisième cas, le diagnostic de MH est retenu, notamment sur le résultat de la TEP. Après corticothérapie, les 3 patients ont présenté une réponse clinique et biologique complète avec disparition des anomalies métaboliques à la TEP de contrôle.

“…Glukoz membran taşıyıcı proteinler (GLUT 1-5) aracılığıyla hücre içine alındıktan sonra heksokinaz II enzimi ile fosforilize edilerek FDG-6-fosfat'a dönüştürülür. Bu kademeden sonra katabolize edilmez ve hücre içinde retansiyon göstere-rek PET görüntüleme yapılmasına olanak verir (2).…”

Section: Pozi̇tron Yayan Radyonükli̇dler Ve Pet Radyofarmasöti̇kleri̇unclassified

Pet-Ct Applications In Thorax - Introduction And Basic Principles

Sönmezoğlu¹

2015

Toraks Cer Bult

Positron Emission Tomography (PET) is a scintigraphic imaging modality where radiopharmaceuticals labeled with positron emitting radionuclides and CT entegrated PET (PET/CT) scanners are used. Although there are numerous PET radiopharmaceutical available in medical literature, F-18 labeled fluorodeoxyglucose (FDG) is the most frequently used PET radiopharmaceutical in routine clinical applications, which is capable of imaging majority of malignant solid tumors. However, Ga-68 labeled peptides have also been very popular recently, in particular for imaging of neuroendocrine tumors and prostate cancers. This special issue is dedicated for clinical applications of FDG-PET/CT imaging in the disease of thorax.